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ABSTRACT 
Background: The safety of the European Society of Cardiology (ESC) 0/1h-algorithm for rapid 
rule-out and rule-in of Non-ST-Segment-Elevation Myocardial Infarction (NSTEMI) using high-
sensitivity cardiac troponin (hs-cTn) has been questioned.  
Objectives: We aimed to validate the diagnostic performance of the 0/1h-algorithm in a large 
multicentre study. 
Methods: We prospectively enrolled unselected patients presenting to the emergency department 
with symptoms suggestive of NSTEMI in six countries. Final diagnosis was centrally 
adjudicated by two independent cardiologists. Hs-cTnT and hs-cTnI blood concentrations were 
measured at presentation and after one hour. Safety of rule-out was quantified by the negative 
predictive value (NPV) for NSTEMI, accuracy of rule-in by the positive predictive value (PPV) 
and overall efficacy by the proportion of patients triaged towards rule-out or rule-in within 1h. 
Results: Prevalence of NSTEMI was 17%. Among 4368 patients with serial hs-cTnT 
measurements available, safety of rule-out (NPV 99.8%, 2488/2493), accuracy of rule-in (PPV 
74.5%, 572/768) and overall efficacy was high by assigning three fourths of patients either to 
rule-out (57%, 2493/4368) or rule-in (18%, 768/4368). Similarly, among 3500 patients with 
serial hs-cTnI measurements, safety of rule-out (NPV 99.7%, 1528/1533), accuracy of rule-in 
(PPV 62.3%, 498/800) and overall efficacy was high by assigning more than two thirds of 
patients either to rule-out (44%, 1533/3500) or rule-in (23%, 800/3500). Excellent safety was 
confirmed in multiple subgroup analyses including patients presenting early (≤3 hours) after 
chest pain onset. 
Conclusions: The ESC 0/1h-algorithm using hs-cTnT and hs-cTnI is very safe and effective in 
triaging patients with suspected NSTEMI.  
 
Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifiers: 
NCT00470587 (APACE) and NCT02355457 (BACC). 
 
Condensed Abstract: The European Society of Cardiology (ESC) recommends the 0/1h-
algorithm using high-sensitivity cardiac troponin (hs-cTn) T or I for rapid rule-out and rule-in of 
Non-ST-Segment-Elevation Myocardial Infarction. However, its safety has been questioned. We 
aimed to validate the diagnostic performance in a large multicentre study. Among 4368 patients 
with available hs-cTnT and 3500 patients with available hs-cTnI measurements, safety of rule-
out (negative predictive value 99.8% and 99.7%, respectively), accuracy of rule-in (positive 
predictive value 74.5% and 62.3%, respectively) and overall efficacy was very high by assigning 
more than two thirds of patients either to rule-out or rule-in within one hour. 
 
Key Words: myocardial infarction, diagnostic algorithms, rule-in, rule-out, diagnosis of 
myocardial infarction, troponin 
 
Abbreviations 
ECG = electrocardiography 
ED = emergency department 
ESC = European Society of Cardiology 
Hs-cTn = high-sensitivity cardiac troponin 
MI = myocardial infarction 
MACE = major adverse cardiac event 
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LR = likelihood ratio 
NPV = negative predictive value 
NSTEMI = Non-ST-Segment-Elevation Myocardial Infarction 
PPV = positive predictive value 
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Introduction 
Patients with symptoms suggestive of myocardial infarction (MI) account for about 10% 
of all emergency department (ED) consultations.(1) Rapid identification of MI as a life-
threatening disorder is important for the early initiation of appropriate, evidence-based, and 
effective therapy.(2,3) Rapid and safe rule-out of MI is also of major medical and economic 
importance as it allows the timely detection and treatment of alternative causes of acute chest 
pain and possible early discharge for outpatient management (2,3). 
Electrocardiography (ECG) and cardiac troponin (cTn) form the diagnostic cornerstones 
for MI and complement clinical assessment (2-4). The clinical introduction of high-sensitivity 
cardiac troponin (hs-cTn) assays has allowed the development of more rapid triage algorithms, 
including the European Society of Cardiology (ESC) 0/1h-algorithm (2-15). The ESC hs-cTn 
0/1h-algorithm, which should always be used in conjunction with all other clinical information 
including clinical assessment and the ECG, uses assay-specific cut-off levels for hs-cTnT and hs-
cTnI derived from dedicated diagnostic studies to triage patients very early to either rule-out or 
rule-in of MI.(2-15). 
Recently, concern has been articulated that this algorithm has not been prospectively 
validated in a large study, that previous studies had not included a sufficient number of early 
presenters (≤3h after chest pain onset) to ensure safety particularly in this vulnerable subgroup 
and that the performance characteristics of the ESC 0/1h-algorithm may not be sufficient for 
routine clinical application.(12,16) We therefore aimed to validate the ESC 0/1h-algorithm in a 
large multicenter diagnostic study with a high number of early presenters.  
Methods 
Study design and population  
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This analysis combined pooled patient-level data from two large diagnostic studies with 
no study-specific interventions to maximize generalizability and particularly the number of early 
presenters: first, the Advantageous Predictors of Acute Coronary Syndrome Evaluation 
(APACE, NCT00470587) study, which is an ongoing prospective international multicentre study 
with twelve centers in five European countries (Switzerland, Italy, Spain, Poland, Czech 
Republic) designed to contribute to advancing the early diagnosis of MI;(5-7,13,17-21) second, 
the Biomarkers in Acute Cardiac Care (BACC, NCT02355457) study, which is an ongoing 
prospective single-center study performed by the University Heart Center Hamburg, 
Germany.(5-8,13,14) Adult patients presenting to the ED with symptoms suggestive of MI such 
as acute chest discomfort and/or angina pectoris were recruited after written informed was 
obtained. In both studies enrolment was independent of renal function, while patients with 
terminal kidney failure on chronic dialysis were excluded in APACE. Each study was carried out 
according to the principles of the Declaration of Helsinki and approved by the local ethics 
committees.  
Patients presenting with ST-segment elevation myocardial infarction were excluded. The 
assay-specific hs-cTnT and hs-cTnI cut-off criteria of the investigated ESC 0/1h-algorithm were 
originally derived in two small subsets of the contributing APACE-study. The present analyses 
include all patients enrolled in the APACE-study with the exception of those patients that 
contributed to the derivation of the ESC 0/1h-hs-cTnT or ESC 0/1h-hs-cTnI-algorithm, as well as 
all patients enrolled in the BACC-study. 
From all the prospectively recruited patients, two diagnostic datasets were constructed: 
Diagnostic dataset A with complete serial hs-cTnT measurements (0h and 1h samples) and 
diagnostic dataset B with complete serial hs-cTnI measurements. The most common reasons for 
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missing samples after one hour were early transfer to the catheter laboratory or coronary care 
unit and diagnostic procedures around the 1h-window that precluded blood draw at one hour. 
(Online Figure 1). 
For the prognostic analyses, a common prognostic dataset was constructed with complete 
serial measurements of hs-cTnT and hs-cTnI. The authors designed the studies, gathered, and 
analysed the data according to the STARD guidelines for studies of diagnostic accuracy(22) 
(Online Table 1), vouched for the data and analysis, wrote the paper, and decided to publish. 
Routine clinical assessment 
Patients underwent clinical assessment that included medical history, physical 
examination, standard blood test including serial measurements of local (hs)-cTn, 12-lead ECG, 
chest radiography (if requested), continuous ECG rhythm monitoring and pulse oximetry. 
Management of patients was left to discretion of the attending physician. 
Adjudicated final diagnosis 
Adjudication of the final diagnosis was performed centrally in each study by two 
independent cardiologists in a dedicated core laboratory applying the universal definition of 
MI(23) using all available medical records obtained during clinical care including history, 
physical examination, results of laboratory testing including serial levels of hs-cTnT, radiologic 
testing, ECG, echocardiography, cardiac exercise test, lesion severity and morphology in 
coronary angiography - pertaining to the patient from the time of ED presentation to 30-day 
follow up for patients in BACC and 90-day follow up for patients in APACE. In situations of 
disagreement about the diagnosis, cases were reviewed and adjudicated in conjunction with a 
third cardiologist.  
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MI was defined and cTn interpreted as recommended in the current guidelines.(1-3,24) In 
brief, MI was diagnosed when there was evidence of myocardial necrosis in association with a 
clinical setting consistent with myocardial ischemia. Myocardial necrosis was diagnosed by at 
least one cTn-value above the 99th percentile together with a significant rising and/or falling. The 
criteria used to define a rise and/or fall in cTn and the cTn-assays available for the adjudication 
are described in detail in the method section in the online-only supplement. All other patients 
were classified in the categories of unstable angina (UA), stable angina (in BACC only; in 
APACE the chest pain episode leading to ED presentation was adjudicated to either UA, if 
ischemic and not fulfilling criteria for MI, or non-cardiac, if non-ischemic), non-cardiac chest 
pain (NCCP), cardiac but non-coronary disease (e.g. tachyarrhythmias, perimyocarditis, 
takotsubo cardiomyopathy, heart failure), and symptoms of unknown origin with normal levels 
of cTn.  
Measurements of hs-cTnT and hs-cTnI 
Blood samples (plasma and serum) were collected at the time of the patient’s presentation 
to the ED and after one hour. Levels of hs-cTnT were determined on the Elecsys® (Roche 
Diagnostics, Rotkreuz, Switzerland) and levels of hs-cTnI on the Architect® (STAT hs-cTnI, 
Abbott Laboratories, IL, USA) analyser (Online Appendix). 
ESC 0/1h-algorithm 
The ESC 0/1h-algorithm, which should always be used in conjunction with all clinical 
information available including the ECG and clinical assessment, triages patients presenting with 
suspected Non-ST-Segment-Elevation Myocardial Infarction (NSTEMI) very early towards rule-
out, observe and rule-in based on assay-specific levels of hs-cTn obtained at presentation and 
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after one hour (Online Figure 2) (2). The specific cut-off levels of hs-cTnT and hs-cTnI had 
been derived in previous diagnostic studies.(2,3,5-15). 
Follow-up 
Patients were contacted 1, 3 and 12 months after discharge by telephone calls or in 
written form. Additionally, information regarding death during follow up was obtained from the 
patient’s hospital notes, the family physician’s records and the national registry on mortality.  
Outcome Measures 
The primary diagnostic endpoint was NSTEMI (type 1 and 2) at presentation to the ED 
while type 1 NSTEMI was the secondary diagnostic endpoint. The primary prognostic endpoint 
was overall mortality at 30 days and one year while the secondary prognostic endpoint was 
major adverse cardiac event (MACE), defined as the composite of overall mortality and MI 
(including the index event), at 30 days and one year. Rule-out safety of the ESC 0/1h-algorithm 
was quantified by the negative predictive value (NPV) and likelihood ratio (LR) for NSTEMI in 
the rule-out group. Accuracy of rule-in, which aims to identify patients eligible for early 
coronary angiography, was quantified by the positive predictive value (PPV) and LR for 
NSTEMI in the rule-in group. Efficacy of the ESC 0/1h-algorithm was quantified by the 
proportion of patients triaged to either rule-out or rule-in. Given previous evidence suggesting 
suboptimal performance of other rapid rule-out approaches in patients presenting to the ED early 
(≤3h) after chest pain onset,(21,25) subgroup analysis in this vulnerable group of early presenters 
was predefined. Additional predefined subgroup analyses were performed according to sex, age 
older than 65 years, pre-existing coronary artery disease, renal dysfunction [defined as 
glomerular filtration rate < 60ml/min/1.73m2], and contributing study cohort.  
Statistical analysis 
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As the ESC 0/1h-Algorithm contains three triage categories (rule-out/observe/rule-in), 
2x3s tables were constructed to assess its diagnostic performance. All diagnostic performance 
measures (proportions, predictive values and LR for NSTEMI in the three triage categories) were 
derived from these 2x3 tables as described in detail in Online Figure 3. Mortality and MACE 
during follow-up was analyzed using Kaplan-Meier survival curves. Net reclassification 
improvement analysis was used to compare the ability of the ESC hs-cTnT and the hs-cTnI 0/1h-
algorithms to correctly classify patients according to risk of one-year mortality and incidence of 
MACE. Further details on the statistical analysis can be found in the method section of the 
Online Appendix.  
Results 
Characteristics of patients 
From May 2006 to April 2016, 5856 patients with suspected MI were recruited in six 
European countries. After exclusion of 234 patients presenting with ST-segment-elevation 
myocardial infarction and patients that were part of the original hs-cTnT or hs-cTnI cutoff 
derivation of the ESC 0/1h-algorithms, 4368 patients with serial samples of hs-cTnT (diagnostic 
dataset A) and 3500 patients with serial samples of hs-cTnI (diagnostic dataset B) were eligible 
for this analysis (Online Figure 1, Table 1). There was an overlap of 3468 patients with both hs-
cTnT and hs-cTnI 0/1h-samples available used for comparison of prognostic performance of hs-
Tn (common prognostic dataset). 
Thirty percent of patients were early presenters (≤3h after chest pain onset) and thirty 
percent were admitted to the ED by ambulance. Baseline characteristics of the two contributing 
studies were clinically comparable, but differed statistically in various baseline characteristics, 
representing an international real-world clinical scenario (Online Table 2). Clinical assessment 
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included a conventional, less sensitive cTn assay in 25%, a sensitive cTn assay in 2% and a hs-
cTn assay in 73%. 
Adjudicated final diagnosis 
The adjudicated final diagnosis was NSTEMI in 735/4368 patients (17%), UA in 
462/4368 (11%), stable angina in 16/4368 (0.4%), cardiac symptoms of origin other than CAD, 
such as tachyarrhythmia, takotsubo cardiomyopathy, heart failure or myocarditis, in 814/4368 
(19%), non-cardiac symptoms in 2226/4368 (51%) and unknown in 115/4368 patients (3%). 
Among the 735 patients presenting with NSTEMI, 572 (78%) were diagnosed as type 1 
NSTEMI. 
Discrepancies between the discharge diagnosis by the treating physician and the 
adjudicated final diagnosis of NSTEMI were present in 5.7% (250/4368) of patients. 
Blood concentrations of hs-cTnT and hs-cTnI 
At ED presentation, concentrations of hs-cTnT and hs-cTnI were significantly higher in 
patients with NSTEMI (median 55ng/L and 93.6ng/L, respectively) as compared to patients with 
other final diagnoses (median 7ng/L and 4.0ng/L, respectively, p<0.001 for comparisons). 
Similarly, absolute 1h-changes were higher in patients with NSTEMI as compared to patients 
with other final diagnoses for both hs-cTn assays (median absolute 1h-change: 10ng/L and 
35.2ng/L versus 1ng/L and 0.7ng/L, respectively, p<0.001 comparisons). Median time between 
the first and second blood draw for serial hs-cTn measurement was 60 [59, 68] minutes with 
90% of all samples collected within 46-84 minutes after the first blood draw. 
Diagnostic performance of the ESC 0/1h-algorithm using hs-cTnT 
The concept and condensed diagnostic performance of the ESC 0/1h-algorithm using hs-
cTnT and hs-cTnI is visualized in the Central Illustration.  
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Using hs-cTnT, the ESC 0/1h-algorithm triaged 57% (2493/4368) of patients towards 
rule-out (Figure 1). Direct rule-out based on 0h-hs-cTnT-concentrations <5ng/L was feasible in 
16% (706/4368) of patients, missing no NSTEMI (NPV 100.0% [706/706]). Overall, safety of 
rule-out was very high (NPV 99.8% [2488/2493]; LR 0.01 [(5/735):(2488/3633)]).  
Rule-in was feasible in 18% (768/4368) of patients with appropriate accuracy (PPV 
74.5%, [572/768], LR 14.43 [(572/735):(196/3633)]). Takotsubo cardiomyopathy, myocarditis, 
heart failure, and unstable angina accounted for 36% of non-MI diagnosis in the rule-in group. 
Overall efficacy was high allowing rule-out or rule-in based on the 0h- and 1h-hs-cTnT-
samples in 75% (3261/4368) of patients. Baseline characteristics and treatment characteristics of 
patients assigned to rule-out, observe and rule-in are listed in Online Tables 3 and 4. Invasive 
management and administration of cardiovascular medication was substantially more frequent in 
the rule-in group as compared to the rule-out group Details on the five NSTEMI-patients (0.1%) 
incorrectly ruled-out by the ESC 0/1h-algorithm are listed in Online Table 5.  
Diagnostic performance of the ESC 0/1h-algorithm using hs-cTnI 
Using hs-cTnI, the ESC 0/1h-algorithm triaged 44% (1533/3500) of patients towards 
rule-out (Figure 2). Direct rule-out based on 0h-hs-cTnT-concentrations <2ng/L was feasible in 
10% (362/3500) of patients, missing no NSTEMI (NPV 100.0% [362/362]). Overall, safety of 
rule-out was very high (NPV 99.7% [1528/1533]; LR 0.02 [(5/588):(1528/2912)]).  
Rule-in was feasible in 23% (800/3500) of patients with appropriate accuracy (PPV 
62.3%, [498/800]; LR 8.17 [(498/588):(302/2912)]). Takotsubo cardiomyopathy, myocarditis, 
heart failure, and unstable angina accounted for 34% of non-MI diagnosis in the rule-in group. 
Overall efficacy was high allowing rule-out or rule-in based on the 0h- and 1h-hs-cTnI-
samples in 67% (2333/3500) of patients. Baseline characteristics and treatment characteristics of 
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patients assigned to rule-out, observe and rule-in are listed in Online Tables 6 and 7. Details on 
the five NSTEMI-patients (0.1%) incorrectly ruled-out by the ESC 0/1h-algorithm are listed in 
Online Table 8. 
Subgroup analysis: 
A) Early presenters 
In patients presenting to the ED early after chest pain onset, e.g. within 3 hours (=early 
presenters; 1322/4368 in diagnostic dataset A, 1064/3500 in diagnostic dataset B), rule-out safety 
and rule-in accuracy of the ESC 0/1h-algorithm were similar to those observed in late presenters 
for both hs-cTnT and hs-cTnI (Table 2, Figure 3).  
B) Other subgroups 
Additional subgroup analyses according to sex, age, presence of coronary artery disease 
and renal dysfunction confirmed very high and comparable rule-out safety and rule-in accuracy 
while differences in overall efficacy could be observed. High performance of the ESC 0/1h-
alghorithm was confirmed in both contributing study cohorts (Online Table 9). 
Diagnostic performance for the diagnosis of type 1 NSTEMI only 
For the diagnosis of type 1 NSTEMI only, rule-out safety of the ESC 0/1h-algorithm, as 
quantified by the NPV and LR, was very high and tended to be even higher as compared to the 
safety for the diagnosis of both type 1 and 2 NSTEMI. In contrast, the PPV and LR of the triage 
towards rule-in decreased and was lower as compared to the main analysis (Online Figure 4). 
Prognostic performance to predict death and MACE during follow-up  
Among the 3468 patients in the common prognostic dataset with both serial hs-cTnT and 
hs-cTnI measurements available (overlap of diagnostic dataset A and B), median follow-up time 
was 390 days [IQR 365-772] and 82% (2854/3468) of patients had completed one-year follow-
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up. Only 0.06% (2/3468) of patients were lost to follow-up within one year. The ESC 0/1h-
algorithm allowed a powerful discrimination between low-risk of all-cause mortality at 30 days 
and one year in the rule-out group (for hs-cTnT 0.1% and 0.8%, respectively; for hs-cTnI 0.1% 
and 1.0%, respectively), intermediate risk in the observational group (for hs-cTnT 0.7% and 
7.2%, respectively; for hs-cTnI 0.4% and 5.7%, respectively), and high-risk in the rule-in group 
(for hs-cTnT 2.8% and 10.4%, respectively; for hs-cTnI 2.5% and 8.0%, respectively; log-rank 
p<0.001 for comparisons between triage strata of each algorithm, Figure 4). Similarly, the ESC 
0/1h-algorithm using both hs-cTnT and hs-cTnI strongly discriminated the risk of MACE 
(including index events) at 30 days and one year in the three strata (Online Figure 5). According 
to net reclassification improvement analysis, the ESC hs-cTnT 0/1h-algorithm was superior to 
the ESC hs-cTnI 0/1h-algorithm to assign risk of one-year mortality (NRI 16.1, p<0.001) and 
one-year MACE (NRI 12.3, p<0.001) within the respective rule-out, observe and rule-in groups. 
Triage by the ESC 0/1h-algorithm using hs-cTnT and hs-cTnI both provided incremental 
prognostic information regarding mortality and incidence of MACE at one year independent of 
NSTEMI diagnosis (Online Table 10). Prognostic findings were confirmed when assessed in the 
diagnostic dataset A and B individually (Online Figures 6 and 7).  
Discussion  
This large multicentre study, including a large subgroup of early presenters (n=1322), 
was performed to address recent concerns regarding the suitability for routine clinical care of the 
new ESC hs-cTn 0/1h-algorithm.(12,16) This algorithm is recommended for use in conjunction 
with all other clinical information including chest pain characteristics(19) and the ECG for the 
early triage of patients presenting with suspected NSTEMI to the ED.(2) We report six major 
findings: 
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First, the safety of the triage towards rule-out of NSTEMI, as quantified by NPV (99.7-
99.8%) and LR (0.01-0.02), was very high for hs-cTnT and hs-cTnI, and similar to the estimates 
observed in previous studies, which had derived the different components of the ESC hs-cTn 
0/1h-algorithm.(2,3,5-15) Second, PPV (62-74%) and LR (8-14) of the triage towards rule-in 
seemed appropriate for the selection of patients eligible for early coronary angiography, which 
may allow the detection and rapid revascularization of the culprit lesion in a large portion of 
NSTEMI patients. In addition, coronary angiography is also required for accurate diagnosis in a 
substantial percentage of patients assigned towards rule-in with diagnoses other than MI 
including Takotsubo cardiomyopathy, myocarditis, heart failure and unstable angina. This 
clinical perspective is critically important when discussing what constitutes an appropriate PPV 
for the rule-in zone.12 Third, the ESC 0/1h-algorithm was highly effective allowing triage of 
more than two thirds of patients towards rule-out or rule-in of MI. Of note, direct rule-out of 
NSTEMI based on a single hs-cTnT/I-concentration was feasible in 16% and 10% and provided 
excellent safety, as no NSTEMI was missed. Fourth, the ESC 0/1h-algorithm overall had similar 
performance characteristics in the vulnerable subgroup of early presenters (<3h) as compared to 
the overall cohort. While the point estimates for NPV, PPV and LR were slightly lower in early 
presenters as compared to late presenters, their 95% confidence intervals widely overlapped and 
clearly reject the hypothesis of a substantially lower performance in early presenters. Also, the 
percentage of patients triaged towards rule-out or rule-in was slightly higher in early presenters 
as compared to late presenters, further documenting the suitability for routine clinical care of the 
ESC 0/1h-algorithm in early presenters. Of note, this is the largest cohort of early presenters ever 
tested for the performance of the ESC 0/1h-algorithm. Robust findings were obtained from 
multiple subgroup analyses including sex, age, presence of coronary artery disease and renal 
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dysfunction, confirming excellent safety of rule-out and reasonable accuracy of rule-in. Fifth, 
the ESC 0/1h-algorithm allowed powerful and reliable risk-stratification of short-term and long-
term risk of mortality and MACE. E.g. 30-day mortality was 29-times and 24-times higher in 
patients triaged towards rule-in as compared to patients triaged towards rule-out with hs-cTnT 
and hs-cTnI, respectively. Sixth, while this study did not aim to directly compare hs-cTnT and 
hs-cTnI, we observed differences in three performance measures between the ESC hs-cTnT 
0/1h-algorithm and the ESC hs-cTnI 0/1h-algorithm in favour of the former. The ESC hs-cTnT 
0/1h-algorithm had higher PPV for NSTEMI, higher efficacy, and also seemed to better risk-
stratify patients regarding long-term mortality. The differences in PPV and efficacy are caused, 
at least to large extent, by the fact that serial measurements of hs-cTnT, but not hs-cTnI were 
part of the extensive clinical information available for the adjudication of the final diagnosis in 
all patients. Accordingly, our methodology provided most accurate and valid estimates for the 
ESC hs-cTnT 0/1h-algorithm, but due to some differences in the hs-cTnT and hs-cTnI signal 
may have slightly underestimated the true performance of the ESC hs-cTnI 0/1h-algorithm (17). 
Similarly, two recent studies using adjudication mainly based on cTnI invariably underestimated 
the true performance of early algorithms using hs-cTnT.(9,12) In contrast, the differences in risk-
prediction are supported by previous studies and likely reflect true pathophysiological 
differences between cTnT and cTnI (18). 
Our findings corroborate and extend previous work on the development and validation of 
safe and effective rule-out and rule-in strategies for NSTEMI and highlight that the hs-cTnT and 
hs-cTnI cut-off levels currently suggested by the ESC balance safety and efficacy well (5-
11,20,26,27). The ESC 0/1h-algorithm using hs-cTnT has been externally validated before in a 
smaller patient cohort, confirming high-safety of rule-out.(9) However, in contrast to this 
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previous study, the present validation study is more than three times larger than the previous 
study, assesses both hs-cTnT and hs-cTnI, uses a hs-cTn-assay for adjudication of goldstandard 
diagnosis and comprises a subset of the vulnerable subgroup of early presenters that is more than 
twice as large, and thereby substantially increases the generalizability of our findings. The 
findings of this study, including the fact that no patient with NSTEMI was missed by both, the 
hs-cTnT and the hs-cTnI algorithm, further corroborate recent observations made in other 
diagnostic studies indicating a small number of patients with discordant hs-cTnT and hs-cTnI 
signals.(9,12) The exact pathophysiological reasons for this phenomenon are unknown, but may 
include patient- and event-related factors, as well as pre-analytical and analytical factors. 
It is important to highlight that all hs-cTn-based diagnostic algorithms should always be 
used in conjunction with all other information available to the clinicians including vital signs, the 
12-lead ECG and chest pain characteristics.(2,4,19) The combination of the ESC 0/1h-algorithm 
with quantified clinical judgment seems particular valuable, as it has been shown to help identify 
patients with unstable angina, the more benign ACS phenotype.(2,10) Moreover, it is important 
to mention that beyond the ESC 0/1h-algorithm, also other early biomarker-based strategies have 
been developed and seem to justify clinical use.(2,4,8,17,20,26-29). 
Study limitations 
Some limitations merit consideration when interpreting these findings. First, our study 
was conducted in ED patients with symptoms suggestive of NSTEMI. Further studies are 
required to quantify the utility of the ESC 0/1h-algorithm in patients with either higher (e.g., in a 
coronary care unit setting) or lower pre-test probability (e.g., in a general practitioner setting) for 
NSTEMI. Second, some patients did not have a 1h-sample and therefore were excluded from 
this analysis. It is very unlikely that the performance of the ESC hs-cTn 0/1h-algorithm would be 
18 
worse in these, particularly as a common reason for a missing blood samples at one hour were 
logistic issues related to e.g. early transfer to the catheter laboratory. Third, although we used 
the most stringent methodology to adjudicate the presence or absence of NSTEMI including 
central adjudication by experienced cardiologists and serial measurements of hs-cTn, we still 
may have misclassified a small number of patients.(3,23) Fourth, the fact that serial 
measurements of hs-cTnT, but not hs-cTnI were part of the extensive clinical information 
available for the adjudication of the final diagnosis in all patients created an important bias for 
the direct comparison of the diagnostic performance of the ESC 0/1h-algorithm using hs-cTnT 
and hs-cTnI. Fifth, we cannot generalize our findings to patients with terminal kidney failure on 
chronic dialysis since they were excluded from one of the two contributing studies and therefore 
underrepresented. 
Conclusions 
In conclusion, this large multicentre study using central adjudication and integrating a 
large population of early presenters was able to address recent concerns regarding the suitability 
for routine clinical care of the new ESC 0/1h-algorithm using hs-cTnT and hs-cTnI and 
documented that it is safe and effective in triaging patients with suspected NSTEMI. 
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Clinical Perspectives 
Competency in Medical Knowledge: The European Society of Cardiology 0/1h-algorithm 
based on high-sensitivity cardiac troponin T or I, used in conjunction with all other clinical 
information including chest pain characteristics and the ECG, is very safe and effective in 
triaging patients with suspected NSTEMI. 
Translational Outlook: Further studies are needed to precisely quantify the clinical impact of 
the 0/1h-algorithm on patients’ management and outcomes observed in the real-life setting. 
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Figure Legends 
Central Illustration: Summarized Performance of the ESC 0/1h-Algorithm. Diagnostic 
performance of the European Society of Cardiology (ESC) 0/1h-algorithm using high-sensitivity 
cardiac troponin T (left column) and I (right column) based on serial blood sampling after one 
hour.  
Figure 1: Diagnostic Performance of the ESC 0/1h- Algorithm using High-Sensitivity 
Cardiac Troponin T. 2x3 table and flow-chart depicting the diagnostic performance of the 
European Society of Cardiology (ESC) 0/1h-algorithm for rapid rule-out and rule-in of 
myocardial infarction among patients presenting with suspected Non-ST-segment-elevation 
myocardial infarction (NSTEMI) using high-sensitivity cardiac troponin T (hs-cTnT, Elecsys®) 
in diagnostic dataset A. 1h change = absolute (unsigned) change of high-sensitivity cardiac 
troponin within the first hour; LR = likelihood ratio; NPV = negative predictive value; PPV = 
positive predictive value. Counts in parentheses in the 2x3 table indicate number of patients 
directly triaged based on the 0h-blood-sample (@0h), only.  *if chest pain onset >3 hours before 
ED presentation. 
Figure 2: Diagnostic Performance of the ESC 0/1h-Algorithm using High-Sensitivity 
Cardiac Troponin I. 2x3 table and flow-chart depicting the diagnostic performance of the 
European Society of Cardiology (ESC) 0/1h-algorithm for rapid rule-out and rule-in of 
myocardial infarction among patients presenting with suspected Non-ST-segment-elevation 
myocardial infarction (NSTEMI) using high-sensitivity cardiac troponin I (hs-cTnI, Architect®) 
in diagnostic dataset B. 1h change = absolute (unsigned) change of high-sensitivity cardiac 
troponin within the first hour; LR = likelihood ratio; NPV = negative predictive value; PPV = 
positive predictive value. Counts in parentheses in the 2x3 table indicate number of patients 
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directly triaged based on the 0h-blood-sample (@0h), only.  *if chest pain onset >3 hours before 
ED presentation. 
Figure 3: Subgroup Analyses on the ESC 0/1h-Algorithm’s Performance. Forest plots 
indicating safety of rule-out, quantified by the negative predictive value (NPV) for Non-ST-
segment-elevation myocardial infarction (left column), accuracy of rule-in, quantified by the 
positive predictive value (PPV, middle column), and overall efficacy, quantified by the 
proportion of patients triaged to rule-out or rule-in (right column) among different predefined 
patients’ subgroups including 95% confidence intervals and interaction p-vales based on the ESC 
0/1h-algorithm (A) using high-sensitivity cardiac troponin T (Elecsys®) and (B) using high-
sensitivity cardiac troponin I (Architect®). CAD = coronary artery disease; CPO = chest pain 
onset; Obs = Observe group; RD = renal dysfunction, defined as estimated glomerular filtration 
rate < 60ml/min/1.73m2; RI = rule-in group; RO = rule-out group. Data on renal function was not 
available in all patients. 
Figure 4: Overall Mortality According to Triage Group by the ESC 0/1h-Algorithm. Kaplan-
Meier curves depicting overall mortality within one year for patients triaged to the rule-out (green 
lines), observe (orange lines) und rule-in (red lines) group by the European Society of Cardiology 
(ESC) 0/1-algorithm using (A) high-sensitivity cardiac troponin T (hs-cTnT, Elecsys®) and (B) 
high-sensitivity cardiac troponin I (hs-cTnI, Architect®).  
  
26 
Table 1: Baseline Characteristics of the Patients in the Diagnostic Dataset A 
 
All patients 
(n=4368) 
NSTEMI 
(n=735) 
No NSTEMI  
(n=3633) 
p-value 
Age – years 62 [50,74] 71 [60,79] 60 [48,73] <0.001 
Male gender 2921 (67) 528 (72) 2393 (66) 0.002 
Risk factors     
Hypertension 2739 (63) 572 (78) 2167 (60) <0.001 
Hypercholesterolemia 1988 (46) 438 (60) 1550 (43) <0.001 
Current smoking 1069 (24) 181 (25) 888 (24) 0.916 
History of smoking 1541 (35) 289 (39) 1252 (34) 0.012 
History     
Coronary artery disease 1459 (33) 340 (46) 1119 (31) <0.001 
Previous MI 919 (21) 237 (32) 682 (19) <0.001 
Peripheral artery disease 236 (5) 81 (11) 155 (4) <0.001 
Previous stroke 258 (6) 50 (7) 208 (6) 0.259 
ECG findings     
ST-segment depression 339 (8) 167 (23) 172 (5) <0.001 
T-wave inversion 373 (9) 100 (14) 273 (8) <0.001 
No significant ECG-changes 3539 (81) 438 (60) 3101 (85) <0.001 
Chest pain characteristics     
Early presenters (≤3h after CPO)  1322 (30) 223 (30) 1099 (30) 0.962 
Hours since chest pain onset* 5.0 [2.0,14.0] 5.5 [2.0,13.0] 5.0 [2.0,14.0] 0.741 
Hours since chest pain peak* 3.0 [1.5,6.5] 3.0 [2.0,8.0] 3.0 [1.5,6.0] 0.025 
Pressure-like chest pain* 1924 (67) 338 (76) 1586 (66) <0.001 
Radiating chest pain* 1694 (59) 289 (65) 1405 (58) 0.009 
Duration >30 minutes* 1782 (62) 273 (61) 1509 (63) 0.596 
Vital signs     
      Heart frequency – bpm 77 [66,89] 80 [68,92] 76 [66,88] <0.001 
      Systolic blood pressure – mmHg 143 [128,159] 145 [128,161] 142 [128,158] 0.055 
      Diastolic blood pressure - mmHg 81 [72,91] 81 [71,92] 82 [73,91] 0.595 
Body mass index - kg/m2 26 [23,29] 27 [24,29] 26 [23,29] 0.017 
Creatinine clearance – ml/min/1.73m2 85 [66,99] 72 [53,89] 87 [70,101] <0.001 
Chronic medication     
ASA 1561 (36) 360 (49) 1201 (33) <0.001 
Anticoagulants 526 (12) 94 (13) 432 (12) 0.495 
B-blockers 1577 (36) 322 (44) 1255 (35) <0.001 
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Numbers are presented as median [q1, q3] or numbers (%). *detailed chest pain characteristics 
only available in the APACE study. ASA = acetylsalicylic acid; ACEI = angiotensin converting 
enzyme inhibitor; ARB = angiotensin receptor blocker; CPO = chest pain onset; ECG = 
electrocardiogram; NSTEMI = Non-ST-Segment-Elevation Myocardial Infarction; Creatinine 
clearance was calculated using CKD-EPI (chronic kidney disease epidemiology collaboration) 
formula. 
Statins 1498 (34) 321 (44) 1177 (32) <0.001 
ACEIs/ARBs 1789 (41) 392 (53) 1397 (38) <0.001 
Calcium antagonists 660 (15) 145 (10) 515 (14) <0.001 
Nitrates 390 (9) 101 (14) 289 (8) <0.001 
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Table 2: Diagnostic Performance of the ESC 0/1h-Algorithm According to Time Between Chest Pain Onset and First Blood Draw 
 
Time 
since 
CPO N 
 Triage Group 
Proportion 
Rule-out 
Proportion 
Direct 
Rule-out 
NPV  
Rule-out 
LR 
Rule-out 
Proportion 
Rule-in 
Proportion 
Direct 
Rule-In 
PPV 
Rule-in  
LR 
Rule-in 
 
Proportion 
Rule-out or 
Rule-In  
Rule-out 
All (direct) 
Observe 
All 
Rule-in 
All (direct) 
Hs-cTnT  
    
         
All Patients any 4368 
no NSTEMI 2488 (706) 949 196 (99) 57% 
(2493/4368) 
16% 
(706/4368) 
99.8% 
(2488/2493) 
0.010 
(5/735):(2488/3633) 
18% 
(768/4368) 
11% 
(482/4368) 
74.5% 
(572/768) 
14.43 
(572/735):(196/3633) 
75% 
(3261/4368) NSTEMI 5 (0) 158 572 (383) 
Late Presenters >3h 3046 
no NSTEMI 1712 (706) 693 129 (75) 56% 
(1713/3046) 
23% 
(706/3046) 
99.9% 
(1712/1713) 
0.003 
(1/512):(1712/2534) 
17% 
(527/3046) 
13% 
(385/3046) 
75.5% 
(398/527) 
15.27 
(398/512):(129/2534) 
74% 
(2240/3046) NSTEMI 1 (0) 133 398 (310) 
Early Presenters ≤3h 1322 
no NSTEMI 776 (n.a.) 256 67 (24) 59% 
(780/1322) 
n.a. 
99.5% 
(776/780) 
0.025 
(4/223):(776/1099) 
18% 
(241/1322) 
7% 
(97/1322) 
72.2% 
(174/241) 
12.80 
(174/223):(67/1099) 
77% 
(1021/1322) NSTEMI 4 (n.a.) 45 174 (73) 
Very Early 
Presenters 
<2h 564 
no NSTEMI 360 (n.a.) 87 26 (8) 64% 
(362/564) 
n.a. 
99.4% 
(360/362) 
0.029 
(2/91):(360/473) 
17% 
(94/564) 
5% 
(31/564) 
72.3% 
(94/564) 
13.59 
(68/91):(26/473) 
81% 
(456/564) NSTEMI 2 (n.a.) 21 68 (23) 
Extremely Early 
Presenters 
<1h 193 
no NSTEMI 125 (n.a.) 29 8 (3) 65% 
(125/193) 
n.a. 
100.0% 
(125/125) 
0.000 
(0/31):(125/165) 
19% 
(36/193) 
5% 
(10/193) 
77.8% 
(28/36) 
18.29 
(28/31):(8/162) 
83% 
(161/193) NSTEMI 0 (n.a.) 3 28 (7) 
Hs-cTnI  
  
         
All Patients any 3500 
no NSTEMI 1528 (362) 1082 302 (169) 44% 
(1533/3500) 
10% 
(362/3500) 
99.7% 
(1528/1533) 
0.016 
(5/588):(1528/2912) 
23% 
(800/3500) 
15% 
(523/3500) 
62.3% 
(498/800) 
8.17 
(498/588):(302/2912) 
67% 
(2333/3500) NSTEMI 5 (0) 85 498 (354) 
Late Presenters >3h 2436 
no NSTEMI 1043 (363) 764 225 (132) 43% 
(1045/2436) 
15% 
(363/2436) 
99.8% 
(1043/1045) 
0.010 
(2/404): (1043/2032) 
23% 
(571/2436) 
17% 
(421/2436) 
60.6% 
(346/571) 
7.73 
(346/404):(225/2032) 
66% 
(1616/2436) NSTEMI 2 (0) 56 346 (289) 
Early Presenters ≤3h 1064 
no NSTEMI 485 (n.a.) 318 77 (37) 46% 
(488/1064) 
n.a. 
99.4% 
(485/488) 
0.030 
(3/184):(485/880) 
22% 
(229/1064) 
10% 
(102/1064) 
66.4% 
(152/229) 
9.44 
(152/184):(77/880) 
67% 
(717/1064) NSTEMI 3 (n.a.) 29 152 (65) 
Very Early 
Presenters 
<2h 443 
no NSTEMI 223 (n.a.) 117 33 (15) 50% 
(223/443) 
n.a. 
100.0% 
(223/223) 
0.000 
(0/70): (223/373) 
21% 
(92/443) 
9% 
(38/443) 
64.1 
(59/92) 
9.53 
(59/70):(33/373) 
71% 
(315/443) NSTEMI 0 (n.a.) 11 59 (23) 
Extremely Early 
Presenters 
<1h 171 
no NSTEMI 78 (n.a.) 58 9 (1) 46% 
(78/171) 
n.a. 
100.0 
(78/78) 
0.000 
(0/26):(78/145) 
19% 
(32/171) 
4% 
(6/171) 
71.9% 
(23/32) 
14.25 
(23/26):(9/145) 
64% 
(110/171) NSTEMI 0 (n.a.) 3 23 (5) 
CPO = chest pain onset; LR = Likelihood ratio; n.a. = not applicable; NPV = negative predictive value; PPV = positive predictive value; Total = 
counts of patients triaged based on 0h- AND 1h-blood-sample; (direct) = counts of patients applicable for direct triage towards rule-out or rule-in 
based on the 0h-blood-sample only. 
